NYSE
$5.10▲ 0.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $183.7MShares out 36.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.15After-hours26.10.16 05:284Ownership#●●●
Evommune, Inc.
Insider Luis C. Pena of Evommune, Inc. reported changes in beneficial ownership of securities as of September 30, 2026. This filing provides the details of the insider's equity transaction via Form 4.…more
$5.10+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 21:018-KKey event
Evommune, Inc.
Evommune announced that its Phase 2a trial for the atopic dermatitis candidate EVO301 met its primary endpoint, achieving a 55% reduction in EASI score at Week 12 compared to placebo. Based on these positive safety and efficacy results, the company plans to initiate a Phase 2b dose-ranging trial using a subcutaneous formulation in mid-2027.…more
$5.10+0.20%vs prev closeView filingShare - 9.23After-hours26.09.24 05:058-KKey event
Evommune, Inc.
Evommune announced that it will present Phase 2a clinical trial data for its atopic dermatitis candidate, EVO301, at the European Academy of Dermatology & Venereology (EADV) Congress held from September 30 to October 3, 2026. The data will be featured in a late-breaking oral session on October 1, and the company anticipates initiating a Phase 2b dose-ranging study for EVO301 in mid-2027.…more
$5.10+0.20%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 21:08#●●●#●●●#●●●
Evommune Presents Positive Phase 2a Data for Atopic Dermatitis Drug EVO301…more
Evommune reported positive therapeutic signals and a favorable safety profile for its atopic dermatitis candidate EVO301 in a Phase 2a trial. The company plans to initiate a subcutaneous Phase 2b dose-ranging study in mid-2027.…more
$5.10+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23After-hours26.09.24 05:06
●●●●●●●● ●●●●● ●●●●●●
Evommune announced that it will present Phase 2a clinical trial data for its atopic dermatitis treatment, EVO301, at the upcoming EADV Congress. The results will be showcased during a late-breaking oral session in Vienna.…more
$5.10+0.20%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 20:40
●●●●●●●● ●●●●● ●●●●●●
Evommune's atopic dermatitis drug candidate, EVO756, failed to meet primary and secondary endpoints in a Phase 2b trial, leading to the discontinuation of the program. The company will now shift its focus toward its other clinical programs, including EVO301 and a migraine prophylaxis study.…more
$5.10+0.20%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report